INTELLECTUAL PROPERTY

Silence has built a strong and diverse intellectual property portfolio including proprietary siRNA delivery technologies, potent siRNA sequences and key siRNA structural features, as well as specific high-value disease targets. 

The company believes that this IP portfolio strategically provides a proprietary position in the RNAi therapeutics space.

At present, the company’s global patent portfolio includes over 200 issued and pending patent applications. Key assets include three exclusive licenses to the issued and pending patents associated with the Zamore "Design Rules" from the University of Massachusetts, as well as a license to the Fire & Mello patent.
 

Silence’s Intellectual Property Toolbox:

KEY IP ASSETS
  • Multiple Layers of Protection for PolyTran and AtuPlex Delivery Technologies
  • Issued Patents on Specific Chemical Modification Patterns
  • Pending and issued IP on 19. 21, 23 and 25mer siRNA Sequences
  • Exclusive License to Three Zamore Patent Families from University of Massachusetts
  • License to Fire & Mello Patent
  • Over 200 Issued and Pending Patent Applications Globally
IP LICENSING PARTNERSHIPS
  • Carnegie Institute
  • Burnham Institute
  • University of Maryland, Baltimore (UMB)
  • Massachusetts Institute of Technology
  • University of Massachusetts Medical School